Literature DB >> 19473417

Functional roles of the factor VIII B domain.

S W Pipe1.   

Abstract

Unravelling the structure, function and molecular interactions of factor VIII (FVIII) throughout its life cycle from biosynthesis to clearance has advanced our understanding of the molecular mechanisms of haemophilia and the development of effective treatment strategies including recombinant replacement therapy. These insights are now influencing bioengineering strategies toward novel therapeutics. Whereas available molecular models and crystal structures have helped elucidate the structure and function of the A and C domains of FVIII, these models have not included detailed structural information of the B domain. Therefore, insights into the role of the FVIII B domain have come primarily from expression studies in heterologous systems, biochemical studies on bioengineered FVIII variants and clinical studies with B domain-deleted FVIII. This manuscript reviews the available data on the potential functional roles of the FVIII B domain. A detailed literature search was performed, and the data extracted were qualitatively summarized. Intriguing emerging evidence suggests that the FVIII B domain is involved in intracellular interactions that regulate quality control and secretion, as well as potential regulatory roles within plasma during activation, platelet binding, inactivation and clearance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19473417     DOI: 10.1111/j.1365-2516.2009.02026.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  34 in total

Review 1.  Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells.

Authors:  Carol H Miao
Journal:  Expert Rev Hematol       Date:  2010-08       Impact factor: 2.929

2.  Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.

Authors:  Joshua I Siner; Benjamin J Samelson-Jones; Julie M Crudele; Robert A French; Benjamin J Lee; Shanzhen Zhou; Elizabeth Merricks; Robin Raymer; Timothy C Nichols; Rodney M Camire; Valder R Arruda
Journal:  JCI Insight       Date:  2016-10-06

3.  Product-dependent anti-factor VIII antibodies.

Authors:  S Butenas; J Krudysz-Amblo; G E Rivard; K G Mann
Journal:  Haemophilia       Date:  2013-04-04       Impact factor: 4.287

4.  Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5.

Authors:  Julie N Pegon; Mohamad Kurdi; Caterina Casari; Soline Odouard; Cécile V Denis; Olivier D Christophe; Peter J Lenting
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

5.  Advances in Overcoming Immune Responses following Hemophilia Gene Therapy.

Authors:  Carol H Miao
Journal:  J Genet Syndr Gene Ther       Date:  2011-12-23

6.  Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization.

Authors:  Alanna McEneny-King; Pierre Chelle; Gary Foster; Arun Keepanasseril; Alfonso Iorio; Andrea N Edginton
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-05-18       Impact factor: 2.745

7.  Complexity and diversity of F8 genetic variations in the 1000 genomes.

Authors:  J N Li; I G Carrero; J F Dong; F L Yu
Journal:  J Thromb Haemost       Date:  2015-10-20       Impact factor: 5.824

8.  Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice.

Authors:  Xuefeng Wang; Richard Y Fu; Chong Li; Chun-Yu Chen; Jenni Firrman; Barbara A Konkle; Junping Zhang; Lei Li; Weidong Xiao; Mortimer Poncz; Carol H Miao
Journal:  Blood Adv       Date:  2020-11-24

9.  Endothelial cell processing and alternatively spliced transcripts of factor VIII: potential implications for coagulation cascades and pulmonary hypertension.

Authors:  Claire L Shovlin; Gillian Angus; Richard A Manning; Grace N Okoli; Fatima S Govani; Kay Elderfield; Graeme M Birdsey; Inês G Mollet; Michael A Laffan; Francesco A Mauri
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

10.  The CDC Hemophilia A Mutation Project (CHAMP) mutation list: a new online resource.

Authors:  Amanda B Payne; Connie H Miller; Fiona M Kelly; J Michael Soucie; W Craig Hooper
Journal:  Hum Mutat       Date:  2012-12-26       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.